Interpace Biosciences® (IDXG) is a dynamic and growing leader in the life sciences industry, providing complex molecular analysis for the early diagnosis and treatment of cancer.
Interpace Diagnostics®, LLC is a subsidiary of Interpace Biosciences and is a fully integrated commercial and bioinformatics company that provides evidence-based, clinically beneficial molecular diagnostic tests and pathology services. Interpace Diagnostics develops and commercializes molecular diagnostic tests that deliver cutting-edge genetic and mutational analysis that help risk-stratify patient samples for thyroid, pancreatic, lung, and other cancers to better inform treatment decisions.
Interpace Biosciences works to assist healthcare providers in the diagnosis, triage, and treatment of patients through advanced diagnostics. The molecular diagnostic tests provided by our subsidiary, Interpace Diagnostics, are supported by rigorous science, provide healthcare providers with the ability to avoid unnecessary surgeries and better assess risk of cancer progression in their patients.
Our molecular diagnostic tests and central laboratory services leverage the latest technology to deliver accurate results.
Our experienced pathologists and Ph.D.’s provide professional support to our customers.
Our molecular diagnostic tests provide unparalleled accuracy and clarity to improve outcomes in patients facing a cancer diagnosis. Interpace Diagnostics currently has five commercialized molecular diagnostic tests in the marketplace: PancraGEN®, ThyGeNEXT®, ThyraMIR®, RespriDX™, and BarreGen®.
All of Interpace Biosciences’ testing services are performed within our clinical reference laboratory located in Pittsburgh, PA, which has Clinical Laboratory Improvement Amendment (CLIA) certification and has been accredited by the College of American Pathologists (CAP).